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Abstract: Bornyl caffeate (1) was previously isolated by us from Valeriana (V.) wallichii 
rhizomes and identified as an anti-leishmanial substance. Here, we screened a small 
compound library of synthesized derivatives 1–30 for activity against schistosomula of 
Schistosoma (S.) mansoni. Compound 1 did not show any anti-schistosomal activity. However, 
strong phenotypic changes, including the formation of vacuoles, degeneration and death were 
observed after in vitro treatment with compounds 23 (thymyl cinnamate) and 27 (eugenyl 
cinnamate). Electron microscopy analysis of the induced vacuoles in the dying parasites 
suggests that 23 and 27 interfere with autophagy. 
Keywords: Schistosoma; schistosomula; parasite; eugenyl cinnamate; thymyl cinnamate; 
vacuoles; autophagy; anti-schistosomal activity 
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1. Introduction 
Schistosomiasis, also known as bilharzia after its discoverer Theodor Bilharz [1], is one of the most 
common chronic diseases of poverty. The disease is found in sub-Saharan Africa, parts of Asia and  
South America [2,3], and is caused by trematodes of the genus Schistosoma which can survive in the 
human host for years or even decades [4]. Of the three principal species infecting humans, S. mansoni is 
the most prevalent [5] causing intestinal schistosomiasis. Infection occurs during contact with freshwater 
bodies that contain the appropriate species of infected snails (Biomphalaria spp. [6]). Free-swimming 
larvae (cercariae) penetrate the skin and reach the bloodstream where they develop into adult worms. 
The infection exhibits a mortality rate of approximately 300,000 deaths a year [7] but is more commonly 
chronic and morbidly debilitating. Disease caused by S. mansoni infection is associated with chronic 
hepatic and intestinal fibrosis, internal varices, which, if located close to the stomach or esophagus can 
result in hematemesis [8,9]. With S. haematobium infections, a variety of urinary system complications 
can result [10]. 
In 2012, 249 million people worldwide were in need of preventive treatment for schistosomiasis with 
praziquantel (PZQ), the only drug available that is active against all species of Schistosoma [11,12]. Although 
there are no reports of clinically relevant resistance to PZQ, recent commitments to increase access to the 
drug mean that we should remain vigilant in the event resistance does arise [13]. It is, therefore, advisable 
to look for alternate drugs to fight this disease. 
We recently discovered that bornyl caffeate (1) from the rhizomes of Valeriana (V.) wallichii 
possessed anti-leishmanial activity [14]. We followed up on this initial finding with the synthesis of a 
small compound library of 28 systematically varied derivatives [15]. Here, we screened the entire library 
(except the cytotoxic acetylated bornyl caffeate) plus three additional compounds (18, 28 and 29) for  
in vitro activity against S. mansoni schistosomula (post-infective larvae) and compounds 23, 27–30 for 
in vitro activity against adult worms. 
2. Results and Discussion 
The compound library and the test results are summarized in Tables 1 and 2. Screens were performed 
at 5 μM and 10 µM against schistosomula and adults, respectively, over the course of 3 days. A previous 
constrained nomenclature is used to record phenotypes [16] (every 24 h) that describe both motion and 
morphological changes. For schistosomula, the terms employed are ‘dead’ (D), ‘degenerate’ (Deg), 
‘round’ (R), ‘overactive’ (O) and ‘dark’ (Dark). After incubation with 23 and 27, we also noted the 
development of internal ‘vacuoles’ (V), which presaged the eventual death of the parasite. 
2.1. Screen Results 
The bornyl caffeate 1 originally isolated and identified from V. wallichii was inactive, whereas some 
of its derivatives proved to be far more potent. In any case, compound 1 shows typical PAINS [17] 
characteristics, namely the catechol moiety and the α,β-unsaturated double bond that are known to give 
false positive results in multiple biochemical assays. As the catechol moiety is prone to oxidation that 
results in the formation of an o-benzoquinone [18], catechols can act as antioxidants or pro-oxidants, 
which can induce damage to DNA or proteins and therefore may result in antiparasitic activity. Omitting 
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the vicinal phenolic hydroxyl groups improved anti-schistosomal activity and reduced cytotoxicity 
significantly. This was the case with bornyl cinnamate (3) as well as thymyl (23) and menthyl cinnamate 
(26), which produced stronger phenotypes than their respective catechol counterparts (1, 21 and 24; see 
Tables 1 and 2). 
Table 1. Results of the screening of compounds 1–10 on schistosomula (Phenotypes:  
D = dead, Deg = degenerate, O = overactive, R = round; severe phenotypes are in bold).  
PZQ = Praziquantel. 
Observed Phenotype After (c = 5 μM) 
Compound R1 R2 R3 R4 24 h 48 h 72 h J774.1 [μM] [15] 
1 -OH -OH -H -H - - - 8.3 
2 -OH -OCH3 -H -H R R, Dark R, Dark 48.7 
3 -H -H -H -H - R, Dark R, Deg 45.2 
4 -H -H -Cl -Cl R - - 58.9 
5 -H -Cl -H -Cl R - - 60.6 
6 -H -OCH3 -H -H R - - 42.6 
7 -H -Br -H -H R - Dark 54.6 
8 -H -N(CH3)2 -H -H R - - >100 
9 -H -OBn -H -H R - - >100 
10 -H -Cl -H -H - Dark - 49.5 
PZQ - - - - O, Dark O, Deg Deg - 
The α,β-unsaturated double bond represents an potentially reactive Michael system. However,  
only the bornyl (3), menthyl (25, 26), thymyl (23) and eugenyl cinnamates (27) induced the severest 
phenotypes. Accordingly, the existence of a Michael system does not necessarily lead to anti-schistosomal 
activity. Also the IC50 of the J774.1 cell line seemed not to be decreased by this Michael system. 
The data also show that cytotoxicity appears not to correlate with anti-schistosomal activity. 
Compounds with highest cytotoxicity (1, 11, 21, 24) have the lowest effect on schistosomula. The most 
potent anti-schistosomal activity is achieved by maintaining the aromatic ring of the cinnamoyl in the 
absence of substituents. 
Overall, the eugenyl cinnamate 27 is the most potent schistosomicidal compound. By 24 h, the 
compound had caused degeneration of the schistosomula with the formation of vacuoles. After 72 h all 
the parasites were dead. Similarly, the thymol cinnamate 23 also led to the formation of vacuoles (V) 
and degeneration (see Table 2). 
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Table 2. Results of the screening of compounds 11–30 on schistosomula (Phenotypes:  
D = dead, Deg = degenerate, O = overactive, R = round, V = vacuoles; severe phenotypes 
are in bold). PZQ = Praziquantel. 
Observed Phenotype After (c = 5 μM) 
Compound R1 R2 R3 24 h 48 h 72 h J774.1 [μM] [15] 
11 isoborneol -OH -OH - - - 8.8 
12 isoborneol -OH -OCH3 - R - 44.3 
13 isoborneol -H -H - - - 46.0 
14 isoborneol -H -NO2 - - - >100 
15 cyclohexanol -H -H - - - >100 
16 geraniol -H -H - - - >100 
17 adamantol -H -H - - - 46.7 
18 4-thujanol -H -H - - - >100 
19 naphthol -H -H - - - 44.5 
20 α-bisabolol -H -H R R - >100 
21 thymol -OH -OH O - - 8.8 
22 thymol -OH -OCH3 - R, Dark Dark, R 45.6 
23 thymol -H -H Deg, V Deg, V Deg 44.8 
24 menthol -OH -OH - R, Dark Dark, R 2.0 
25 menthol -OH -OCH3 R R, Dark R, Deg 45.6 
26 menthol -H -H R R, Dark R, Deg 44.8 
27 eugenol -H -H Deg, V Deg D 32.2 
28 thymol - - - - - >100 
29 eugenol - - - - - >100 
30 borneol - - - - - >100 
PZQ - - - O, R O, Deg Deg - 
The most active cinnamates were again synthesized without the double bond (28–30). However, these 
were inactive. By comparison, the bornyl phenylpropionate (30) retained anti-leishmanial activity [15]. 
For schistosomula, it is possible that the Michael system is responsible for inducing the vacoules—as 
seen with 23 and 27—and is an essential component to the pharmacophore. 
Finally, 23 and 27–30 were selected for screening against adult worms. No effect on the parasites was 
observed at a concentration of 10 µM over the course of 3 days (data not shown). The vulnerability of 
the schistosomula may be due to the major transcriptional, translational and structural changes taking 
place as part of the adaptive process to the mammalian host, in contrast to adult worms which are  
fully adapted. 
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2.2. Analysis of Vacuoles 
Vacuoles are often indicators for autophagy [19] and contribute to the recycling of misfolded proteins 
and harmful cell products [20]. Interestingly, this mechanism seems to be induced by compounds 23 and 
27. The clear induction of the vacuoles by 24 h is followed by death. Light microscopic images (Figure 1) 
reveal multiple large vacuoles inside the schistosomula. 
 
Figure 1. Microscopic images of schistosomula; control group (A,C,E) and treated with  
5 µM 27 (B,D,F) after 24, 48 and 72 h. The vacuoles (V) are prominent after 24 and 48 h, 
whereas by 72 h the somules are dead. Scale bar = 0.2 mm. 
A similar phenotype was induced by 23 (data not shown). We further analyzed the vacuoles induced 
by the eugenyl cinnamate 27 and thymyl cinnamate 23 using transmission electron microscopy (TEM, 
Figure 2). The images generated were compared to those previously reported [21]. The formation of 
large vacuoles in the parasite was promoted by both compounds in a similar fashion. Inside the vacuoles, 
resembling possible autophagolysosomes, multiple internal membranes (a,b) and onion-like multi-lamellar 
structures (b) were found. A fusion of two vacuoles is depicted in (B). 
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Figure 2. Transmission electron micrographs of S. mansoni schistosomula exposed for  
24 h to 5 µM 27 (A) or 23 (B). Enlargements of marked areas in (A,B) are depicted in (a,b), 
respectively. A fusion event between vacuoles is pictured in (B). Vacuoles with internal 
membranes (a,b) and onion-like multi-lamellar structures are visible (b). CM, circular 
muscle; f, flame cell; MS, multi-lamellar structures; STC, nucleus of subtegumental cell; T, 
tegument; V, vacuoles. 
These observations are consistent with the description of autophagy as a defense mechanism in 
Mycobacterium tuberculosis infected macrophages by Gutierrez et al. [22]. Autophagy is employed as 
a clean-up process to remove intracellular pathogens. The characteristics of autophagosomes include a 
double membrane (which is digested in autophagolysosomes during autophagic flux) and the presence 
of cytosolic content, e.g., membranes from captured organelles [23]. Therefore, the observed vacuoles 
in schistosomula may represent the late stage of autophagolysosomes, which occurs after the fusion of 
autophagosomes with lysosomes that contain multiple hydrolases (e.g., cysteine proteases) to degrade 
the enveloped cytosolic material. A downstream blockade of the autophagic flux, e.g., by inhibition of 
the hydrolases needed to degrade the vacuole content [24], may lead to the formation of the huge 
vacuoles observed in schistosomula after exposure to 23 and 27. There are few reports on autophagy in 
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S. mansoni. Autophagy is inducible in S. mansoni schistosomula upon starvation [25] and large 
acidophilic compartments [26,27] are detectable using the fluorescent dye monodansylcadaverine,  
a relatively specific dye for autophagosomes [28]. Exposure of S. mansoni adult worms to astiban, 
lucanthone, hycanthone, and niridazole generate autophagic activities in the gastrodermis (gut) of  
S. mansoni and induce autophagic vacuoles [29]. There appear to be no reports on autophagy in 
schistosomes that is induced by cinnamic acid derivatives or terpenoids. Eugenol is considered to act as 
an antifungal [30] and antibacterial [31] as has also been suggested for thymol and other terpenoids [32], 
but the mechanisms of their respective actions have not been investigated. Interestingly, eugenol alone 
is also known to inhibit autophagy by preventing the dissociation of the Beclin1-Bcl2 heterodimer in 
A549 cells cotransfected with pMN-Bcl2 and pMC-Beclin1 [33]. As the Beclin1-Bcl2 complex is also 
present in Schistosoma [34] the eugenyl as well as the thymyl derivatives may influence the autophagy 
process in the same way. However, further studies are required. 
3. Experimental Section 
3.1. General Information 
IR spectra were recorded on a JASCO FT/IR-6100 Fourier Transformation Infrared Spectrometer 
(Easton, MD, USA) equipped with an ATR unit. 1H (400.132 MHz) and 13C (100.613 MHz) NMR 
spectra were recorded on a Bruker Avance 400 Ultra Shield™ (Bruker Biospin, Ettlingen, Germany) 
spectrometer. The signals of the deuterated solvents were used as internal standards (CDCl3: 1H 7.26 
ppm, 13C 77.0 ppm). Starting materials and reagents for the synthesis were purchased from Sigma-Aldrich 
(Steinheim, Germany) and VWR (Darmstadt, Germany). For TEM an EM 900 transmission electron 
microscope (Carl Zeiss AG, Oberkochen, Germany) was used. 
3.2. Synthesis and Cytotoxicity Assays 
The synthesis and full spectroscopic data of compounds 1–17, 19–27 and 30 were reported  
previously [15]. Compounds 18, 28 and 29 were synthesized via Steglich esterification as explained 
there. The protocol for the cytotoxicity studies against J774.1 was as described [35]. 
Thujanyl cinnamate (18): colorless sirup; IR (ATR) νmax 2955, 2930, 2869, 1702, 1636, 1163 cm−1;  
1H-NMR (CDCl3, 400 MHz) δ (ppm) 7.60 (1H, d, J = 16.0 Hz), 7.50 (2H, m), 7.37 (3H, m), 6.38 (1H, 
d, J = 16.0 Hz), 2.10 (1H, m), 1.87 (1H, m), 1.79 (1H, m), 1.64 (3H, s), 1.60 (1H, m), 1.39 (1H, m), 1.27 
(1H, m), 0.92 (3H, d, J = 6.8 Hz), 0.91 (3H, d, J = 6.8 Hz), 0.45 (1H, m), 0.32 (1H, dd, J = 3.7, 5.2 Hz);  
13C-NMR (CDCl3, 100 MHz) δ (ppm): 166.5, 143.5, 134.7, 130.0, 128.8 (2C), 128.0 (2C), 120.2, 91.9, 
34.8, 34.6, 32.2, 31.2, 25.6, 21.5, 20.0, 19.7, 13.3. 
Thymyl phenylpropanoate (28): colorless liquid; IR (ATR) νmax 3027, 2962, 2925, 2869, 1754, 1505, 
1497, 1413, 1148 cm−1; 1H-NMR (CDCl3, 400 MHz) δ (ppm) 7.35–7.24 (5H, m), 7.17 (1H, d,  
J = 7.9 Hz), 7.01 (1H, d, J = 7.9 Hz), 6.72 (1H, s), 3.10 (2H, m), 2.90 (2H, m), 2.80 (1H, sept, J = 6.9 Hz), 
2.30 (3H, s), 1.12 (6H, d, J = 6.9 Hz); 13C-NMR (CDCl3, 100 MHz) δ (ppm): 171.6, 147.8, 140.2, 137.0, 
136.5, 128.6 (2C), 128.4 (2C), 127.1, 126.4 (2C), 122.6, 35.9, 31.0, 27.0, 23.0 (2C), 20.8. 
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Eugenyl phenylpropanoate (29): colorless liquid; IR (ATR) νmax 2963, 2936, 2924, 1756, 1503, 1122 cm−1; 
1H-NMR (CDCl3, 400 MHz) δ (ppm) 7.36-7.23 (5H, m), 6.90 (1H, d, J = 8.0 Hz), 6.80 (1H, d,  
J = 1.9 Hz), 6.78 (1H, dd, J = 1.9, 8.0 Hz), 5.98 (1H, m), 5.14 (1H, m), 5.10 (1H, m), 3.80 (3H, s), 3.40 
(2H, m), 3.12 (2H, m), 2.93 (2H, m); 13C-NMR (CDCl3, 100 MHz) δ (ppm): 171.1, 150.9, 140.4, 139.0, 
138.0, 137.1, 128.5 (2C), 128.4 (2C), 126.3, 122.5, 120.7, 116.1, 112.7, 55.8, 40.1, 35.6, 31.0. 
3.3. Schistosoma Screens and TEM 
Maintenance of the S. mansoni life cycle, preparation of schistosomula and adult worms, compound 
storage and treatment of schistosomula and adult worms were as described [16]. Compounds were 
dissolved in DMSO. Control assays contained the same amount of DMSO. The compound names, 
structures and phenotypes arising are listed in Tables 1 and 2. PZQ served as anti-schistosomal reference 
drug. TEM studies were performed as follows. After treatment with compound 27 for 24 h schistosomula 
were fixed for 45 min with 2.5% glutaraldehyde-50 mM cacodylate (pH 7.2; Sigma-Aldrich, Steinheim, 
Germany) at room temperature and then contrasted for 2 h at 4 °C with 2% OsO4 buffered with 50 mM 
cacodylate (pH 7.2). The material was washed with distilled water, and incubated overnight at 4 °C with 
0.5% uranyl acetate in distilled water. The parasites were dehydrated and embedded in EPON. Ultrathin 
sections were mounted on 300-mesh grids, stained with uranyl acetate and lead citrate, and analyzed 
with an EM 900 transmission electron microscope (Carl Zeiss AG, Oberkochen, Germany). 
4. Conclusions 
We screened a library of 30 derivatives of bornyl caffeate (1) for anti-schistosomal activity against 
schistosomula and adult worms of S. mansoni. Adults were refractory to all of the compounds. For 
schistosomula, the compound eugenyl cinnamate (27) was lethal. Prior to death, this compound and 
thymyl cinnamate (23) induced the appearance of multiple internal vacuoles, which may indicate an 
induction of autophagy, although this hypothesis requires formal testing. No direct correlation between 
cytotoxicity (vs. J774.1 cells) and anti-schistosomal activity was found. Further studies with an expanded 
series of compounds and including dose-response relationships are necessary to determine whether these 
compounds represent a basis for future anti-schistosomal drugs. 
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